0001193125-14-294742.txt : 20140805 0001193125-14-294742.hdr.sgml : 20140805 20140805090359 ACCESSION NUMBER: 0001193125-14-294742 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20140805 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140805 DATE AS OF CHANGE: 20140805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Actavis plc CENTRAL INDEX KEY: 0001578845 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55075 FILM NUMBER: 141014769 BUSINESS ADDRESS: STREET 1: 70 SIR JOHN ROGERSON'S QUAY CITY: DUBLIN 2 STATE: L2 ZIP: 2 BUSINESS PHONE: (216) 523-5000 MAIL ADDRESS: STREET 1: 70 SIR JOHN ROGERSON'S QUAY CITY: DUBLIN 2 STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: Actavis Ltd DATE OF NAME CHANGE: 20130607 8-K 1 d768203d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 5, 2014

 

 

ACTAVIS plc

(Exact Name of Registrant as Specified in Charter)

 

 

 

Ireland   000-55075   98-1114402

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

1 Grand Canal Square, Docklands

Dublin 2, Ireland

(Address of Principal Executive Offices)

(862) 261-7000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

 

 

Item 7.01. Regulation FD Disclosure.

On August 5, 2014, Actavis plc (the “Company”) announced that beginning with the second quarter of 2014, the Company is presenting its Actavis Pharma Segment Revenues inclusive of the results of key North American promoted brands.

Exhibit 99.1 to this Form 8-K provides Actavis Pharma Segment Revenue inclusive of the results of key North American promoted brands for the three months ended June 30, 2014, March 31, 2014, December 31, 2013, September 30, 2013, June 30, 2013 and March 31, 2013, the six months ended June 30, 2014 and the twelve months ended December 31, 2013, December 31, 2012 and December 31, 2011. The attached Exhibit 99.1 does not represent a restatement of previously issued financial statements and does not affect the Company’s reported net income, earnings per share, total assets, or stockholders’ equity for any of the previously reported periods. The information contained in this Form 8-K is being furnished pursuant to Regulation FD in order to provide the financial community with historical financial data that is presented on a basis consistent with the Company’s additional reporting.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

d. Exhibits:

 

99.1    Actavis Pharma Segment Revenue for the three months ended June 30, 2014, March 31, 2014, December 31, 2013, September 30, 2013, June 30, 2013 and March 31, 2013, the six months ended June 30, 2014 and the twelve months ended December 31, 2013, December 31, 2012 and December 31, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 5, 2014       ACTAVIS plc
    By:  

/s/ R. Todd Joyce

      R. Todd Joyce
      Chief Financial Officer

EXHIBIT INDEX

 

Exhibit

No.

    Description
99.1    Actavis Pharma Segment Revenue for the three months ended June 30, 2014, March 31, 2014, December 31, 2013, September 30, 2013, June 30, 2013 and March 31, 2013, the six months ended June 30, 2014 and the twelve months ended December 31, 2013, December 31, 2012 and December 31, 2011
 EX-99.1 2 d768203dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Actavis Pharma Segment Revenue

 

(Unaudited; $ in millions)   Six Months
Ended
June 30,
2014		     Three Months
Ended
June 30,
2014		     Three Months
Ended
March 31,
2014		     Twelve Months
Ended
December 31,
2013		     Three Months
Ended
December 31,
2013		     Three Months
Ended
September 30,
2013		     Three Months
Ended
June 30,
2013		     Three Months
Ended
March 31,
2013		     Twelve Months
Ended
December 31,
2012		     Twelve Months
Ended
December 31,
2011		  

North American Brands

                    

Lo Loestrin® Fe

   $ 130.4      $ 68.0      $ 62.4      $ 63.3      $ 63.3      $ —        $ —        $ —        $ —        $ —     

Minastrin® 24 Fe

     104.4        56.5        47.9        55.7        55.7        —          —          —          —          —     

Estrace® Cream

     111.2        57.9        53.3        60.7        60.7        —          —          —          —          —     

Other Women’s Health

     97.4        48.4        49.0        113.1        44.9        26.9        21.3        20.0        61.9        32.5   
 

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Women’s Health

     443.4        230.8        212.6        292.8        224.6        26.9        21.3        20.0        61.9        32.5   

Rapaflo®

     56.5        25.3        31.2        96.5        25.8        26.8        21.3        22.6        71.1        55.6   

Delzicol®/Asacol® HD

     277.2        136.4        140.8        150.2        150.2        —          —          —          —          —     

Other Urology/Gastroenterology

     106.0        52.8        53.2        162.1        60.1        33.4        34.5        34.1        146.6        153.4   
 

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Urology/Gastroenterology

     439.7        214.5        225.2        408.8        236.1        60.2        55.8        56.7        217.7        209.0   

Doryx®

     29.4        17.5        11.9        31.0        31.0        —          —          —          —          —     

Actonel ®

     115.3        54.2        61.1        63.1        63.1        —          —          —          —          —     

Other Dermatology/Established Brands

     153.4        70.2        83.2        266.8        80.3        65.9        67.7        52.9        198.6        190.6   
 

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Dermatology/Established Brands

     298.1        141.9        156.2        360.9        174.4        65.9        67.7        52.9        198.6        190.6   

Total North American Brands

     1,181.2        587.2        594.0        1,062.5        635.1        153.0        144.8        129.6        478.2        432.1   

North American Generics

     2,055.6        1,031.4        1,024.2        3,915.7        1,033.1        976.1        949.8        956.7        3,472.2        2,945.6   

International

     1,268.3        621.6        646.7        2,502.5        728.1        576.8        619.4        578.2        978.1        430.5   
 

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Net Revenues

   $ 4,505.1      $ 2,240.2      $ 2,264.9      $ 7,480.7      $ 2,396.3      $ 1,705.9      $ 1,714.0      $ 1,664.5      $ 4,928.5      $ 3,808.2   
 

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Our North American Brands Revenue consists of three categories: Women’s Health, Urology/Gastroenterology, and Dermatology/Established Brands. The products that make up each category are as follows:

 

Women’s Health

  

Urology/Gastroenterology

   

Dermatology/Established Brands

Atelvia®   Androderm®    Cordran® Tape   Tri-Norinyl®
Crinone®   Asacol®    Doryx®   Oxytrol®
Estrace® Cream   Asacol® HD/Asacol® 800    Actonel®   Gelnique®
Generess® Fe   Delzicol®    Actonel DR®   Sodium Ferric Gluconate
Lo Loestrin® Fe   Enablex®    INFeD®   Actigall®
Loestrin® 24 Fe   Rapaflo®    Kadian®   Condylox®
Minastrin® 24 Fe   Trelstar®    Alora®   Fioricet®
Fibristal™  

AndroGel® Copromotion

Revenue

    Brevicon®   Fiorinal®
     ella®   Norco®
     Estrace® Tablets   Microzide®
     Femring®   Femcon® Fe
     Norinyl®   femhrt®
     Nor-QD®   Sarafem®
     PapSure®   Estrostep® Fe
     PreQue 10™   Ovcon®
       Royalty, Supply & Other Revenue